Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.   HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis. It previously received Orphan Drug Designation from FDA.   Research conducted at NC State University to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cel...